文献速递心境障碍

营养品与植物药治疗重性抑郁障碍:系统综述与网络Meta分析

Nutraceuticals and phytoceuticals for the treatment of major depressive disorder: a systematic review and network meta-analysis.
PubMed 文献 · Mol Psychiatry · 2026-09-01

该网络Meta分析纳入163项RCT(n=15,757),评估营养品/植物药治疗重性抑郁障碍的疗效与可接受性。经低偏倚风险等限制后,二十碳五烯酸(EPA)、维生素D3和圣约翰草提取物ZE117对抑郁症状的效应量高于预期,但证据置信度低至极低。

要点

  • EPA、维生素D3和圣约翰草提取物ZE117在严格限制分析中显示优于安慰剂的抑郁症状改善。
  • 姜黄素在低偏倚风险分析中对焦虑减轻显示中等效应量。
  • 总体异质性高(I²=85.3%),证据置信度低至极低,需更严谨试验。

核心结论

  • 过滤低质量证据后,仅少数营养品/植物药对抑郁症状显示潜力,需更严谨试验验证。

研究设计与样本

  • 系统综述与网络Meta分析,检索PubMed/MEDLINE/EMBASE/Scopus/PsycINFO/CENTRAL/ClinicalTrials.gov至2025年7月1日,纳入随机对照试验(RCT)。
  • 共纳入163项研究(n=15,757),涉及137种不同化合物组合。

主要发现

  • 在限制为≥2项RCT、非TAU抗抑郁药、低偏倚风险、非赞助试验、非离群值的分析中,EPA(k=20,n=8483;SMD=-1.67;95%CI=-2.38至-0.97)、维生素D3(k=3,n=344;SMD=-1.59;95%CI=-2.71至-0.46)和圣约翰草提取物ZE117(k=3,n=207;SMD=-1.02;95%CI=-1.90至-0.15)对抑郁症状的效应量高于预期。
  • 姜黄素在低偏倚风险分析中对焦虑减轻显示中等效应量(k=2,n=89;SMD=-0.58;95%CI=-0.99至-0.18)。
  • 存在显著异质性(I²=85.3%;95%CI=81.9%至88.0%)和整体不一致性(Q-between-designs=186.91,p<0.0001),但无发表偏倚。
  • Shugan颗粒、EPA、EPA+二十二碳六烯酸、ZE117及氟西汀+EPA在治疗反应上显著优于安慰剂;圣约翰草提取物WS5570/ZE117在症状缓解上显著优于安慰剂。
  • 西替考林与安慰剂相比显著增加脱落率;Meta回归显示效应量越大与AMSTAR-Plus评分越低相关,提示研究质量较低。

关键数值与推荐

  • 主要结局为抑郁症状变化(SMD)、治疗反应和全因脱落(可接受性,RR)。
  • 次要结局为焦虑症状变化、不良事件相关脱落(耐受性)和症状缓解。
  • 证据置信度评估为低至极低。

临床怎么用

  • 临床决策中应考虑EPA、维生素D3和圣约翰草提取物ZE117的潜在获益,但需告知患者证据质量低。
  • 不推荐西替考林用于重性抑郁障碍,因其显著增加脱落率。

局限性

  • 纳入研究存在显著异质性和不一致性,证据置信度低至极低。
  • 部分化合物分析基于少量RCT和小样本,效应量估计不精确。
  • Meta回归提示较大效应量与较低研究质量相关,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: "Nutraceuticals" and "phytoceuticals" may have antidepressant activity, prompting an in-depth network meta-analysis of randomized clinical trials (RCTs). METHODS: Systematic review and network meta-analysis (PubMed/MEDLINE/EMBASE/Scopus/PsycINFO/CENTRAL/ClinicalTrials.gov (until 01/07/2025) of RCTs vs. placebo or treatment as usual (TAU = antidepressants) testing nutraceuticals/phytoceuticals in major depressive disorder (MDD). Change in depressive symptomatology (standardized-mean-difference = SMD), treatment response, and all-cause discontinuation (acceptability) (risk ratio = RR) were co-primary outcomes. Secondary outcomes were anxiety symptom changes, adverse event-related discontinuation ("tolerability"), and symptom remission. We conducted subgroup, transitivity, and sensitivity analyses to explore/reduce heterogeneity, and assessed global/local inconsistency, publication bias, risk of bias (RoB), and confidence in the evidence (CINeMA/AMSTAR-Plus). RESULTS: Across 163 studies (n = 15,757, distinct compounds' combinations n = 137), several molecules/classes outperformed placebo with very large effect sizes. Restricting analyses to compounds with ≥2RCTs/non-TAU antidepressants/low RoB/non-sponsored trials/non-outliers, higher-than-expected/unrealistic effect sizes emerged vs. placebo for eicosapentaenoic acid (EPA) (k = 20, n = 8483; SMD = -1.67;95%C.I. = -2.38;-0.97), vitamin D3 (k = 3, n = 344; SMD = -1.59;95%C.I. = -2.71;-0.46), and St. John's-wort-extract-ZE117 (k = 3,n = 207;SMD = -1.02;95%C.I = -1.90;-0.15) regarding depressive symptomatology. Substantial heterogeneity (I2 = 85.3%;95%C.I. = 81.9%;88.0%) and global inconsistency (Q-between-designs = 186.91, p < 0.0001) emerged, explained by subgroup and sensitivity analyses, without publication bias. Additionally, a medium effect size emerged vs. placebo for curcumin (k = 2,n = 89;SMD = -0.58;95%C.I. = -0.99;-0.18) regarding anxiety reduction in low RoB analyses. Shugan granules, EPA, EPA+Docosahexaenoic Acid, ZE117, and fluoxetine+EPA response and St. John's wort extract WS5570/ZE117 remission significantly outperformed placebo. Citicoline was associated with significantly more dropouts than placebo. A meta-regression of efficacy effect sizes against adapted AMSTAR-Plus scores showed that larger SMDs were associated with lower AMSTAR scores, indicating lower study quality. Confidence in the evidence was low to very low. CONCLUSIONS: Upon filtering low-quality evidence, only a few nutraceutical/phytoceuticals showed potential for depressive symptoms, warranting more rigorous trials.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fornaro M, Di Lorenzo C, Nunez N, et al. Nutraceuticals and phytoceuticals for the treatment of major depressive disorder: a systematic review and network meta-analysis. Mol Psychiatry. 2026. PMID: 42680855. doi:10.1038/s41380-026-03759-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。